Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Target to $21
Jefferies upgrades Aurinia Pharmaceuticals to Buy, boosting the price target to $21 on strong Lupkynis sales and promising pipeline prospects.
/ 2 items
Jefferies upgrades Aurinia Pharmaceuticals to Buy, boosting the price target to $21 on strong Lupkynis sales and promising pipeline prospects.
A top FDA official flagged the drug voclosporin as highly toxic, noting it was approved too quickly using ‘stand-in’ results (surrogate endpoints) without proving a direct benefit to patients. The FDA will now review this process to ensure approved drugs deliver real clinical results.